PETHEMA Foundation clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 106 studies whose lead sponsor is PETHEMA Foundation. 11 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.
Keep track of what changes. Save the PETHEMA Foundation studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesFocus areas
Conditions PETHEMA Foundation leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 106. Browse all 106 →
- Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)RecruitingNCT07478991Phase 3
- Inotuzumab as Post-Trasplantation Therapy for Adult High-risk B-cell Precursor Acute Lymphoblastic LeukemiaNot yet recruitingNCT07862946Phase 2
- Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML PatientsRecruitingNCT07507760Phase 2
- NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-IberdomideRecruitingNCT05558319Phase 3
- Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT06544785Phase 2
- Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple MyelomaNot yet recruitingNCT07637526
- Treatment for Ph-negative ALL for Adults up to 65 YearsNot yet recruitingNCT07443592Not applicable
- Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)RecruitingNCT07045909Phase 2
- Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple MyelomaRecruitingNCT06574126Phase 2
- Treatment Protocol for Newky Diagnosed Adult Ph Positive ALLNot yet recruitingNCT06175702
- Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in AdultsRecruitingNCT04179929Not applicable
- Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid LeukemiaCompletedNCT04230239Phase 2
- Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard ChemotherapyActive, not recruitingNCT04090736Phase 3
- Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug ClassesActive, not recruitingNCT06282978Phase 2
- Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years OldCompletedNCT04687761Phase 1/2
- Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to LenalidomideActive, not recruitingNCT05060627Phase 1/2
- Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple MyelomaActive, not recruitingNCT05849610Phase 2
- Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Newly Diagnosed Patients.Active, not recruitingNCT05527340Phase 2
- Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)CompletedNCT04107727Phase 2
- Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma PatientsActive, not recruitingNCT04802356Phase 2
- SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple MyelomaActive, not recruitingNCT03589222Phase 2
- Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic LeukemiaCompletedNCT04178798Phase 3
- Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With OfatumumabStatus unknownNCT03280160Phase 2
- Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCTStatus unknownNCT05218603
- A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients According to the Routinely Used Genetic and Biologic MarkersCompletedNCT05541224
- Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 YearsActive, not recruitingNCT03742297Phase 3
- Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple MyelomaActive, not recruitingNCT02415413Phase 2
- Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple MyelomaStatus unknownNCT03336073Phase 2
- Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) in Spain.Status unknownNCT05297240
- PETHEMA-BLIN-01/PET069014 (BLIN-01)TerminatedNCT03523429Phase 2
- Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) PatientsCompletedNCT02384083Phase 1/2
- Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 YearsStatus unknownNCT01376427Not applicable
- A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First TreatmentStatus unknownNCT04112589Phase 1/2
- Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic LeukemiaStatus unknownNCT02776605Phase 2
- GEM-CLARIDEX: Ld vs BiRdStatus unknownNCT02575144Phase 3
- Study of Prognostic Factors in Adult Lymphoblastic LymphomaStatus unknownNCT03571997
- PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 YearsStatus unknownNCT01358201Phase 4
- Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVEStatus unknownNCT01491763Phase 4
- Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)Status unknownNCT01366898Phase 4
- Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.Status unknownNCT05049473Phase 2
- Molecular Diagnostic Platform for AMLStatus unknownNCT04446741
- REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic LeukemiaTerminatedNCT03742323Phase 1/2
- Epidemiologic Registry PETHEMA LMA 2015Status unknownNCT02607059
- PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 YearsStatus unknownNCT01296178Not applicable
- Clinical Guidelines for APL TreatmentStatus unknownNCT02020161Phase 4
- Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.CompletedNCT03311815
- Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03477643
- VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 YearsCompletedNCT02606825
- Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AMLCompletedNCT03661515Phase 1
- Pembrolizumab (MK-3475) in MM Patients With Residual DiseaseCompletedNCT02636010Phase 2